Acta Neuropathologica

, Volume 125, Issue 5, pp 621–636

What do we know about IDH1/2 mutations so far, and how do we use it?


DOI: 10.1007/s00401-013-1106-9

Cite this article as:
Horbinski, C. Acta Neuropathol (2013) 125: 621. doi:10.1007/s00401-013-1106-9


Whole genome analyses have facilitated the discovery of clinically relevant genetic alterations in a variety of diseases, most notably cancer. A prominent example of this was the discovery of mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) in a sizeable proportion of gliomas and some other neoplasms. Herein the normal functions of these enzymes, how the mutations alter their catalytic properties, the effects of their d-2-hydroxyglutarate metabolite, technical considerations in diagnostic neuropathology, implications about prognosis and therapeutic considerations, and practical applications and controversies regarding IDH1/2 mutation testing are discussed.



Supplementary material

401_2013_1106_MOESM1_ESM.doc (40 kb)
Supplementary material 1 (DOC 40 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of PathologyUniversity of KentuckyLexingtonUSA